Kalpit Patel
Stock Analyst at B. Riley Securities
(0.83)
# 3,858
Out of 4,964 analysts
59
Total ratings
30.23%
Success rate
-11.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $7.24 | +65.75% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $41.75 | +43.71% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $7.08 | +97.74% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $19.21 | +92.61% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $39.31 | -38.95% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.43 | +144.76% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $9.23 | -2.49% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $5.01 | +99.60% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.24 | +464.52% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $9.90 | +304.04% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.25 | +140.00% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $18.44 | +8.46% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.12 | +628.16% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $16.32 | +120.59% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.26 | +3,882.30% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.18 | +1,425.42% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.97 | +153.81% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.82 | +574.76% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $11.15 | +572.65% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $7.24
Upside: +65.75%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $41.75
Upside: +43.71%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $7.08
Upside: +97.74%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $19.21
Upside: +92.61%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $39.31
Upside: -38.95%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.43
Upside: +144.76%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $9.23
Upside: -2.49%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.01
Upside: +99.60%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.24
Upside: +464.52%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.90
Upside: +304.04%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.25
Upside: +140.00%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $18.44
Upside: +8.46%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.12
Upside: +628.16%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $16.32
Upside: +120.59%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.26
Upside: +3,882.30%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.18
Upside: +1,425.42%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.97
Upside: +153.81%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $14.82
Upside: +574.76%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $11.15
Upside: +572.65%